MX2022006934A - Inhibidor de aldosterona sintasa. - Google Patents
Inhibidor de aldosterona sintasa.Info
- Publication number
- MX2022006934A MX2022006934A MX2022006934A MX2022006934A MX2022006934A MX 2022006934 A MX2022006934 A MX 2022006934A MX 2022006934 A MX2022006934 A MX 2022006934A MX 2022006934 A MX2022006934 A MX 2022006934A MX 2022006934 A MX2022006934 A MX 2022006934A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydroimidazo
- cyanophenyl
- disorders
- diseases
- relates
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 abstract 1
- CLPFFLWZZBQMAO-CQSZACIVSA-N 4-[(5r)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-CQSZACIVSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
La presente invención se refiere a un compuesto seleccionado de (R)-(+)-5-(p-cianofenil)-5,6,7,8-tetrahidroimidazo[1,5-a]piridina y su sal farmacéuticamente aceptable, y en particular a la sal de fosfato de (R)-(+)-5-(p-cianofenil)-5,6,7,8-tetrahidroimidazo[1,5- a]piridina, ambas tienen preferiblemente un exceso enantiomérico de la forma (R) mayor o igual al 97%. Además, la presente invención se refiere a composiciones farmacéuticas que comprenden las mismas, su uso como un medicamento y en métodos de tratamiento de enfermedades y trastornos en seres humanos, que incluyen las mujeres en edad fértil y pacientes pediátricos en los que la sobreexposición a la aldosterona contribuye a los efectos nocivos de dichas enfermedades o trastornos, así como los procesos para preparar dichos compuestos inventivos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413635P | 2016-10-27 | 2016-10-27 | |
| EP16205019 | 2016-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006934A true MX2022006934A (es) | 2022-07-11 |
Family
ID=60162205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004937A MX2019004937A (es) | 2016-10-27 | 2017-10-26 | Inhibidor de aldosterona sintasa. |
| MX2022006934A MX2022006934A (es) | 2016-10-27 | 2019-04-26 | Inhibidor de aldosterona sintasa. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004937A MX2019004937A (es) | 2016-10-27 | 2017-10-26 | Inhibidor de aldosterona sintasa. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10822332B2 (es) |
| EP (1) | EP3532056A1 (es) |
| JP (2) | JP7130636B2 (es) |
| KR (2) | KR102506380B1 (es) |
| CN (2) | CN109890389B (es) |
| AU (2) | AU2017350484B2 (es) |
| BR (1) | BR112019007954A2 (es) |
| CA (1) | CA3040803A1 (es) |
| CL (1) | CL2019001131A1 (es) |
| IL (2) | IL301471A (es) |
| MX (2) | MX2019004937A (es) |
| SG (1) | SG11201903803UA (es) |
| ZA (1) | ZA201903149B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10822332B2 (en) * | 2016-10-27 | 2020-11-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5428160A (en) * | 1982-12-21 | 1995-06-27 | Ciba-Geigy Corporation | Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives |
| MTP1076B (en) | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
| MXPA02010091A (es) | 2000-04-12 | 2003-02-12 | Novartis Ag | Novedoso uso medico de inhibidores de sintasa de aldosterona solos o en combinacion con antagonistas del receptor at-1. |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1842543A1 (en) * | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| SG11201404061YA (en) * | 2012-01-17 | 2014-08-28 | Novartis Ag | New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor |
| US10822332B2 (en) * | 2016-10-27 | 2020-11-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
-
2017
- 2017-10-26 US US16/345,209 patent/US10822332B2/en active Active
- 2017-10-26 EP EP17787936.8A patent/EP3532056A1/en active Pending
- 2017-10-26 KR KR1020197011358A patent/KR102506380B1/ko active IP Right Grant
- 2017-10-26 SG SG11201903803UA patent/SG11201903803UA/en unknown
- 2017-10-26 CN CN201780065333.4A patent/CN109890389B/zh active Active
- 2017-10-26 JP JP2019522665A patent/JP7130636B2/ja active Active
- 2017-10-26 BR BR112019007954A patent/BR112019007954A2/pt unknown
- 2017-10-26 MX MX2019004937A patent/MX2019004937A/es unknown
- 2017-10-26 KR KR1020237007198A patent/KR20230037680A/ko not_active Application Discontinuation
- 2017-10-26 IL IL301471A patent/IL301471A/en unknown
- 2017-10-26 AU AU2017350484A patent/AU2017350484B2/en active Active
- 2017-10-26 CA CA3040803A patent/CA3040803A1/en active Pending
- 2017-10-26 CN CN202210638632.5A patent/CN114853755A/zh active Pending
-
2019
- 2019-04-16 IL IL266056A patent/IL266056B2/en unknown
- 2019-04-25 CL CL2019001131A patent/CL2019001131A1/es unknown
- 2019-04-26 MX MX2022006934A patent/MX2022006934A/es unknown
- 2019-05-20 ZA ZA2019/03149A patent/ZA201903149B/en unknown
-
2020
- 2020-08-12 US US16/991,856 patent/US11447491B2/en active Active
-
2022
- 2022-03-01 AU AU2022201401A patent/AU2022201401B2/en active Active
- 2022-08-09 US US17/883,732 patent/US20230047158A1/en active Pending
- 2022-08-24 JP JP2022133021A patent/JP2022176994A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10822332B2 (en) | 2020-11-03 |
| IL266056B1 (en) | 2023-04-01 |
| CN114853755A (zh) | 2022-08-05 |
| AU2022201401B2 (en) | 2024-02-15 |
| KR20190071715A (ko) | 2019-06-24 |
| US11447491B2 (en) | 2022-09-20 |
| KR20230037680A (ko) | 2023-03-16 |
| CL2019001131A1 (es) | 2019-09-06 |
| JP2019532975A (ja) | 2019-11-14 |
| JP2022176994A (ja) | 2022-11-30 |
| JP7130636B2 (ja) | 2022-09-05 |
| MX2019004937A (es) | 2019-06-24 |
| BR112019007954A2 (pt) | 2019-07-02 |
| US20190292180A1 (en) | 2019-09-26 |
| US20230047158A1 (en) | 2023-02-16 |
| CN109890389A (zh) | 2019-06-14 |
| CN109890389B (zh) | 2022-07-01 |
| SG11201903803UA (en) | 2019-05-30 |
| ZA201903149B (en) | 2020-02-26 |
| AU2022201401A1 (en) | 2022-03-24 |
| AU2017350484A1 (en) | 2019-05-23 |
| KR102506380B1 (ko) | 2023-03-03 |
| CA3040803A1 (en) | 2018-05-03 |
| US20210024519A1 (en) | 2021-01-28 |
| IL266056B2 (en) | 2023-08-01 |
| AU2017350484B2 (en) | 2021-12-02 |
| EP3532056A1 (en) | 2019-09-04 |
| IL301471A (en) | 2023-05-01 |
| IL266056A (en) | 2019-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA107952C2 (uk) | ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| NZ751418A (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| MX2023000782A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
| TN2016000227A1 (fr) | Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides. | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| MX356683B (es) | Derivados de triazolpiridazinas 6-sustituidas como agonistas rev-erb. | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12020550341A1 (en) | Niraparib formulations | |
| MX2020006587A (es) | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. | |
| GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| WO2018038988A3 (en) | Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them | |
| PH12019501324A1 (en) | Pyrazolo[3,4-b]pyridines and imidazo [1,5-b] pyridazines as pde1 inhibitors | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| MX362197B (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos. | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| PH12018501489A1 (en) | Compounds and compositions for the treatment of cryptosporidiosis | |
| MY195169A (en) | Cyclic Ether Derivatives of Pyrazolo[1,5-A]Pyrimidine-3-Carboxyamide | |
| MX2022006934A (es) | Inhibidor de aldosterona sintasa. | |
| MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |